{"title": "RXi Pharmaceuticals Presents Additional Positive Phase 2 Efficacy Results for Combination of NeuVaxTM (E75) and Tras", "author": null, "url": "https://www.fiercebiotech.com/biotech/rxi-pharmaceuticals-presents-additional-positive-phase-2-efficacy-results-for-combination", "hostname": "fiercebiotech.com", "description": "NeuVax (E75) when combined with trastuzumab in low to intermediate HER2 positive patients demonstrated 0% recurrence at 24 months, with an excellent safety and tolerability profileCombination of | NeuVax (E75) when combined with trastuzumab in low to intermediate HER2 positive patients demonstrated 0% recurrence at 24 months, with an excellent safety and tolerability profileCombination of", "sitename": "FierceBiotech", "date": "2011-06-08", "cleaned_text": "Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Subscribe Biotech Cell & Gene Therapy Clinical Data Venture Capital Deals Research Medtech Devices Diagnostics AI and Machine Learning CRO Special Reports Fierce 50 Resources Fierce Events Industry Events Webinars Podcasts Whitepapers Survey Events Subscribe Fierce Pharma Fierce Biotech Fierce Healthcare Fierce Life Sciences Events Advertise About Us "}